Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP)

Authors

  • Silvia Calabria Fondazione ReS (Ricerca e Salute) – Research and Health Foundation, Roma - Italy https://orcid.org/0000-0001-9345-2855
  • Manenti Lucio Azienda Socio-Sanitaria Liguria 5, Nephrology Unit, La Spezia - Italy https://orcid.org/0000-0002-4144-2142
  • Giulia Ronconi Fondazione ReS (Ricerca e Salute) – Research and Health Foundation, Roma - Italy https://orcid.org/0000-0002-5502-8110
  • Carlo Piccinni Fondazione ReS (Ricerca e Salute) – Research and Health Foundation, Roma - Italy https://orcid.org/0000-0002-8648-8961
  • Leonardo Dondi Fondazione ReS (Ricerca e Salute) – Research and Health Foundation, Roma - Italy
  • Letizia Dondi Fondazione ReS (Ricerca e Salute) – Research and Health Foundation, Roma - Italy https://orcid.org/0009-0001-3168-6856
  • Antonella Pedrini Fondazione ReS (Ricerca e Salute) – Research and Health Foundation, Roma - Italy
  • Immacolata Esposito Drugs and Health Srl, Roma - Italy
  • Alice Addesi Drugs and Health Srl, Roma - Italy
  • Filippo Aucella Medical Sciences Department, “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo (FG) - Italy https://orcid.org/0000-0003-1027-7049
  • Nello Martini Fondazione ReS (Ricerca e Salute) – Research and Health Foundation, Roma - Italy

DOI:

https://doi.org/10.33393/grhta.2024.2696

Keywords:

Costs, Dialysis, End-stage kidney disease, Italy, Retrospective analysis, RWE, Treatment, Uremic pruritus

Abstract

Background: Chronic kidney disease-associated pruritus (CKD-aP) affects patients on hemodialysis. This study identified hemodialysis patients presumably affected or not affected by CKD-aP and integrated healthcare costs, from the perspective of the Italian administrative healthcare data.

Methods: Through cross-linkage of Italian administrative healthcare data collected between 2015 and 2017 (accrual period) in the database of Fondazione ReS (Ricerca e Salute), patients undergoing in-hospital/outpatient hemodialysis were selected. Cohorts with and without CKD-aP were created based on the presence/absence of CKD-aP-related treatment (according to common clinical practice and guidelines) supplies and assessed in terms of CKD-aP-related treatments and mean healthcare costs per capita paid by the Italian National Health Service (INHS).

Results: Of 1,239 people on hemodialysis for ≥2 years, CKD-aP affected 218 patients. Patients with CKD-aP were older and with more comorbidities. During the follow-up year, on average, the INHS spent €37,065 per case, €31,286 per control and € 35,988 per non-CKD-aP subject. High-efficiency dialytic therapies performed to people on hemodialysis with CKD-aP largely weighed on the overall mean annual cost.

Conclusions: This real-world study identified patients on chronic hemodialysis potentially treated for CKD-aP. Interestingly, high-efficiency dialysis seems the most frequent and expensive choice for the treatment of CKD-aP. The discovery of appropriate and effective treatments for this condition might offer cost offsets.

Downloads

Download data is not yet available.

References

Sukul N, Karaboyas A, Csomor PA, et al. Self-reported pruritus and clinical, dialysis-related, and patient-reported outcomes in hemodialysis patients. Kidney Med. 2020;3(1):42-53.e1. https://doi.org/10.1016/j.xkme.2020.08.011 PMID:33604539 DOI: https://doi.org/10.1016/j.xkme.2020.08.011

Kim D, Pollock C. Epidemiology and burden of chronic kidney disease-associated pruritus. Clin Kidney J. 2021 Oct;14(suppl 3):i1-i7. https://doi.org/10.1093/ckj/sfab142. DOI: https://doi.org/10.1093/ckj/sfab142

van der Willik EM, Lengton R, Hemmelder MH, et al. Itching in dialysis patients: impact on health-related quality of life and interactions with sleep problems and psychological symptoms—results from the RENINE/PROMs registry. Nephrol Dial Transplant. 2022;37(9):1731-1741. https://doi.org/10.1093/ndt/gfac022 PMID:35098998 DOI: https://doi.org/10.1093/ndt/gfac022

Kimata N, Fuller DS, Saito A, et al. Pruritus in hemodialysis patients: results from the Japanese Dialysis Outcomes and Practice Patterns Study (JDOPPS). Hemodial Int. 2014;18(3):657-667. https://doi.org/10.1111/hdi.12158 PMID:24766224 DOI: https://doi.org/10.1111/hdi.12158

Mettang T, Kremer AE. Uremic pruritus. Kidney Int. 2015;87(4):685-691. https://doi.org/10.1038/ki.2013.454 PMID:24402092 DOI: https://doi.org/10.1038/ki.2013.454

Millington GWM, Collins A, Lovell CR, et al. British Association of Dermatologists’ guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018. Br J Dermatol. 2018;178(1):34-60. https://doi.org/10.1111/bjd.16117 PMID:29357600 DOI: https://doi.org/10.1111/bjd.16186

Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European S2k guideline on chronic pruritus. Acta Derm Venereol. 2019;99(5):469-506. https://doi.org/10.2340/00015555-3164 PMID:30931482 DOI: https://doi.org/10.2340/00015555-3164

Ting SW, Fan PC, Lin YS, et al. Association between uremic pruritus and long-term outcomes in patients undergoing dialysis. J Am Acad Dermatol. 2020;83(3):924-925. https://doi.org/10.1016/j.jaad.2020.01.011 PMID:31940463 DOI: https://doi.org/10.1016/j.jaad.2020.01.011

Aresi G, Rayner HC, Hassan L, et al. Reasons for underreporting of uremic pruritus in people with chronic kidney disease: a qualitative study. J Pain Symptom Manage. 2019;58(4):578-586.e2. https://doi.org/10.1016/j.jpainsymman.2019.06.010 PMID:31228535 DOI: https://doi.org/10.1016/j.jpainsymman.2019.06.010

Istituto Nazionale di Statistica and ISTAT. Resident population by age, sex and marital status. 2015. https://www.istat.it/it/files//2016/02/Indicatori-demografici_2015.pdf. Accessed December 2023.

Piccinni C, Cevoli S, Ronconi G, et al. Insights into real-world treatment of cluster headache through a large Italian database: prevalence, prescription patterns, and costs. Expert Rev Clin Pharmacol. 2021;14(9):1165-1171. https://doi.org/10.1080/17512433.2021.1934448 PMID:34030566 DOI: https://doi.org/10.1080/17512433.2021.1934448

Maggioni AP, Dondi L, Andreotti F, et al. Prevalence, clinical impact and costs of hyperkalaemia: special focus on heart failure. Eur J Clin Invest. 2021;51(8):e13551. https://doi.org/10.1111/eci.13551 PMID:33786826 DOI: https://doi.org/10.1111/eci.13551

Ronconi G, Dondi L, Calabria S, et al. Real-world prescription pattern, discontinuation and costs of ibrutinib-naïve patients with chronic lymphocytic leukemia: an Italian healthcare administrative database analysis. Clin Drug Investig. 2021;41(7):595-604. https://doi.org/10.1007/s40261-021-01044-3 PMID:34032988 DOI: https://doi.org/10.1007/s40261-021-01044-3

WHO. Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2023. https://www.whocc.no/atc_ddd_index/. Accessed May 2023.

Ministero del Lavoro, della salute e delle politiche sociali. Classificazione delle malattie, dei traumatismi, degli interventi chirurgici e delle procedure dagnostiche e terapeutiche. Versione italiana della ICD9-CM. 2007. https://www.salute.gov.it/imgs/C_17_pubblicazioni_2251_allegato.pdf. Accessed December 2023.

CINECA—Interuniversity Consortium. https://www.cineca.it/. Accessed May 2023.

Società Italiana di Nefrologia. Registro italiano di dialisi e trapianto [Italian Registry of Dialysis and Transplantation]. https://ridt.sinitaly.org/. Accessed May 2023.

Verduzco HA, Shirazian S. CKD-associated pruritus: new insights into diagnosis, pathogenesis, and management. Kidney Int Rep. 2020;5(9):1387-1402. https://doi.org/10.1016/j.ekir.2020.04.027 PMID:32954065 DOI: https://doi.org/10.1016/j.ekir.2020.04.027

Simonsen E, Komenda P, Lerner B, et al. Treatment of uremic pruritus: a systematic review. Am J Kidney Dis. 2017 Nov;70(5):638-655. https://doi.org/10.1053/j.ajkd.2017.05.018 PMID:28720208 DOI: https://doi.org/10.1053/j.ajkd.2017.05.018

van Oosten MJM, Logtenberg SJJ, Edens MA, et al. Health claims databases used for kidney research around the world. Clin Kidney J. 2020;14(1):84-97. https://doi.org/10.1093/ckj/sfaa076 PMID:33564408 DOI: https://doi.org/10.1093/ckj/sfaa076

Agenzia Italiana del Farmaco. Nota 89. GU Serie Generale n.259 del 04-11-2004 2004. https://www.aifa.gov.it/nota-89. Accessed December 2023.

Agenzia Italiana del Farmaco. Nota 4. Farmaco in nota: duloxetina, gabapentin, pregabalin. https://www.aifa.gov.it/nota-04. Accessed December 2023.

Arzhan S, Roumelioti ME, Unruh ML. Itch and ache on dialysis: new approaches to manage uremic pruritus and restless legs. Blood Purif. 2020;49(1-2):222-227. https://doi.org/10.1159/000504081 PMID:31851986 DOI: https://doi.org/10.1159/000504081

Trachtenberg AJ, Collister D, Rigatto C. Recent advances in the treatment of uremic pruritus. Curr Opin Nephrol Hypertens. 2020;29(5):465-470. https://doi.org/10.1097/MNH.0000000000000625 PMID:32740217 DOI: https://doi.org/10.1097/MNH.0000000000000625

Additional Files

Published

2024-01-15

How to Cite

Calabria, S., Lucio, M., Ronconi, G., Piccinni, C., Dondi, L., Dondi, L., Pedrini, A., Esposito, I., Addesi, A., Aucella, F., & Martini, N. (2024). Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP). Global and Regional Health Technology Assessment, 11(1), 22–30. https://doi.org/10.33393/grhta.2024.2696

Issue

Section

Original Research Articles

Categories

Received 2023-10-24
Accepted 2023-11-29
Published 2024-01-15

Metrics

Most read articles by the same author(s)